Camostat-d6 (hydrochloride)
目录号 : GC47022
A neuropeptide with diverse biological activities
Cas No.:2930627-60-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Camostat-d6 is intended for use as an internal standard for the quantification of camostat by GC- or LC-MS. Camostat (50 µM) inhibits entry of vesicular stomatitis virus (VSV) particles pseudotyped with severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 surface glycoprotein in Calu-3 cells and primary human lung epithelial cells.1 It reduces the number of SARS-CoV-2 genomic equivalents, a marker of infection, in Calu-3 cells. Camostat inhibits sodium channel function in human airway epithelial cells (IC50 = 50 nM) and enhances mucociliary clearance in sheep.2 Dietary administration of camostat (1 mg/kg) inhibits the production of TNF-α and chemokine (C-C motif) ligand 2 (CCL2) by monocytes, as well as proliferation of pancreatic stellate cells in a rat model of pancreatic fibrosis.3
1.Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitorCell181(2)271-280(2020) 2.Maianti, J.P., McFedries, A., Foda, Z.H., et al.Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormonesNature511(7507)94-98(2014) 3.Gibo, J., Ito, T., Kawabe, K., et al.Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activityLab Invest.85(1)75-89(2005)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2681 mL | 11.3404 mL | 22.6809 mL |
| 5 mM | 0.4536 mL | 2.2681 mL | 4.5362 mL |
| 10 mM | 0.2268 mL | 1.134 mL | 2.2681 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。